Tag: Cancer: Skin
Benefit of Adjuvant Dabrafenib + Trametinib Persists in Melanoma
Long-term benefit seen for relapse-free survival in stage III disease with BRAF V600E, V600K mutations
Follow-up Calls After Mohs Surgery Do Not Boost Satisfaction
But calls made the evening of dermatology surgery can identify patients with active pain
Topical Calcineurin Inhibitors Not Tied to Skin Cancer
No increased risk seen with topical calcineurin versus topical corticosteroids in adults with dermatitis
Malpractice Fears, Patient Safety Drive Skin Doctors to Order Extra Tests
In a survey, dermatopathologists cite patient safety, malpractice fears as reason to use extra patient services
U.S. Burden of Skin and Subcutaneous Diseases Increasing
Increases seen across all 50 states, with geographic variation in percentage
Vitamin D May Cut Colitis Risk for Immune Checkpoint Inhibitors
Odds of developing ICI colitis significantly reduced with vitamin D use in patients with melanoma
Racial Differences Seen in Time to Treatment for Melanoma
Time from diagnosis to definitive surgery is twice as long on average for black versus white patients
Melanoma Risk From Biologic Therapy Remains Uncertain
Systematic literature review and meta-analysis reveal link to increased risk cannot be ruled out
PFS Prolonged With Continuous Dabrafenib, Trametinib in Melanoma
Median PFS longer with continuous versus intermittent treatment, but overall survival similar
Patients Underestimate Length of Mohs Surgery Scars
Physicians more accurately estimate scar length and can help set expectations
